In Silico Study of SARS-CoV-2 Vaccine Candidate: Spike Glycoprotein

Authors

  • Arif Nur Muhammad Ansori

DOI:

https://doi.org/10.37506/ijfmt.v15i2.14732

Keywords:

Allergenicity Prediction, COVID-19, In Silico Cloning, Toxicity Prediction, Vaccine.

Abstract

This study aimed to perform the analysis of toxicity prediction, allergenicity prediction, and in silico cloning
of peptides originated from SARS-CoV-2 spike glycoprotein in the previous study. Allergenicity prediction
employed AllerPred to predict the non-allergen peptides and toxicity prediction performed using ToxinPred.
Then, this study designed the in silico cloning of SARS-CoV-2 spike glycoprotein with pET-28a(+) using
SnapGene software. Therefore, this study successfully constructed the SARS-CoV-2 vaccine candidate via
in silico method. Therefore, these data could be used to design a peptide-based vaccine against SARSCoV-2. However, the advanced study is recommended confirmation, such as in vitro and in vivo study

Author Biography

Arif Nur Muhammad Ansori

Doctoral Student, Doctoral Program in Veterinary Science, Faculty of Veterinary Medicine, Universitas Airlangga,
Surabaya, Indonesia

Published

2021-03-24

How to Cite

Arif Nur Muhammad Ansori. (2021). In Silico Study of SARS-CoV-2 Vaccine Candidate: Spike Glycoprotein. Indian Journal of Forensic Medicine & Toxicology, 15(2), 2402-2405. https://doi.org/10.37506/ijfmt.v15i2.14732